FIELD: biotechnology.
SUBSTANCE: present invention relates to the field of biotechnology, specifically to a new conjugate of a stabilized agonist of a glucagon-like peptide-1 (GLP-1) receptor; it can be used in medicine. The invention allows for producing the conjugate with improved pharmacological properties: delayed release balances the agonist stability with the speed of release in the organism environment, providing its longer action in comparison with known analogues.
EFFECT: invention can be used in medicinal practice, when treating patients suffering from diabetes or other similar metabolic disorders, using schemes including the administration of a dose once a month or less.
16 cl, 16 dwg, 2 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PRODRUGS CONTAINING HYALURONIC ACID CONJUGATE, LINKER AND DOUBLE AGONIST GLP-1/GLUCAGON | 2016 |
|
RU2719482C2 |
| USE OF LONG-ACTING GLP-1 PEPTIDES | 2013 |
|
RU2657573C2 |
| PRODRUG COMPOSITIONS BASED ON CROSS-LINKED HYALURONIC ACID HYDROGEL AND METHODS OF THEIR PRODUCTION | 2018 |
|
RU2812787C2 |
| METHODS OF DIABETES TREATMENT AND BODY WEIGHT REDUCTION | 2006 |
|
RU2421237C2 |
| CONTROLLED RELEASE COMBINATION THERAPY WITH CNP AGONISTS | 2017 |
|
RU2768747C2 |
| EXENATIDE ANALOGUE | 2020 |
|
RU2823623C1 |
| LONG-ACTING DOUBLE AGONIST OF GLUCAGON-LIKE PEPTIDE-1 AND GLUCAGON RECEPTORS | 2021 |
|
RU2799327C1 |
| PTH COMPOUNDS WITH LOW PEAK-TO-MINIMUM RATIOS | 2017 |
|
RU2766959C2 |
| FUSED DRUG CONSTRUCTS AND CONJUGATES | 2005 |
|
RU2428431C2 |
| COMPOSITION FOR TREATING DIABETES, CONTAINING LONG-ACTING INSULIN CONJUGATE AND LONG-ACTING INSULINOTROPIC PEPTIDE CONJUGATE | 2012 |
|
RU2606840C2 |
